Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
AUTHORIZED USE IN THE U.S.
INDICATION (U.S.)
SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
IMPORTANT SAFETY INFORMATION
Contraindications
Do not administer SPIKEVAX to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of SPIKEVAX.
Warnings and Precautions
Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of SPIKEVAX.Myocarditis and Pericarditis: Post marketing data demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. The observed risk is highest in males 18 years through 24 years of age.Syncope (fainting): May occur in association with administration of injectable vaccines, including SPIKEVAX. Procedures should be in place to avoid injury from fainting.Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to SPIKEVAX.Limitations of Vaccine Effectiveness: SPIKEVAX may not protect all vaccine recipients.
Adverse Reactions
The most commonly reported (≥10%) adverse reactions following any dose in any indicated patient population were pain at the injection site, headache, fatigue, myalgia, chills, arthralgia, axillary swelling/tenderness, nausea/vomiting, swelling at the injection site, erythema at the injection site, and fever.
Reporting Adverse Events and Vaccine Administration Errors
The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967.
Please see the SPIKEVAX Full Prescribing Information.
Please see the Moderna COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine for more information.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's regulatory submission to the U.S. FDA for its Spikevax 2025-2026 formula, including the potential for approval in the U.S. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:Chris RidleyGlobal Head of Media Relations+1 617-800-3651Chris.Ridley@modernatx.com
Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 617-209-5834Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
an hour ago
- UPI
AAP recommends children receive COVID-19 vaccine
The American Academy of Pediatrics is recommending children as young as six months receive the COVID-19 vaccine, despite the Trump administration stating it is not necessary for healthy children. File Photo by John Angelillo/UPI | License Photo Aug. 20 (UPI) -- The United States' leading pediatrics association is recommending that children as young as six months old be inoculated against COVID-19, going against the Trump administration, which stopped recommending healthy children receive the vaccine. The American Academy of Pediatrics made the recommendation Tuesday in the publication of its childhood and adolescent immunization schedule for this year. The report specifically recommends that children be inoculated against COVID-19 between the ages of six and 23 months, stating that those in this age range are at the highest risk of suffering the worst effects of the disease. "Children younger than 2 years old are especially vulnerable to severe COVID-19 and should be prioritized for vaccination unless they have a known allergy to the vaccine or its ingredients," the AAP said in a release accompanying the report. The AAP recommendation goes against that of Health and Human Services Secretary Robert F. Kennedy Jr., who in late May said the U.S. Centers for Disease Control and Prevention was no longer recommending that "healthy children" be immunized against COVID-19. Kennedy, a known vaccine skeptic, cited "a lack of any clinical data" to support booster COVID-19 shots for children. That move prompted AAP and other leading medical groups to sue Kennedy in July for making "unilateral, unscientific changes" to federal vaccine policy, calling it an "assault on science public health and evidence-based medicine." "This administration is an existential threat to vaccination in America, and those in charge are only just getting started," Richard Hughes IV, partner at Epstein Becker Green and lead counsel in the case, said in a statement. "If left unchecked, Secretary Kennedy will accomplish his goal of ridding the United States of vaccines, which would unleash a wave of preventable harm on our nation's children." Kennedy in June also fired all members of the CDC's Advisory Committee on Immunization Practices and replaced them with his own appointees, including three who have spoken out against the COVID-19 vaccine, two of whom have served as witnesses in lawsuits against vaccine makers and one who served on the board of the nation's oldest anti-vaccine group.
Yahoo
2 hours ago
- Yahoo
MBX Biosciences Submits IND for Once-Monthly Obesity Drug
MBX Biosciences Inc. (NASDAQ:MBX) is one of the best IPO stocks to buy according to Wall Street analysts. On June 16, MBX Biosciences announced the submission of an Investigational New Drug/IND application to the US FDA for MBX 4291. This drug is a long-acting GLP-1/GIP receptor co-agonist prodrug being developed for the treatment of obesity. The company's President and CEO, Kent Hawryluk, stated that MBX 4291 is designed to be a potential once-monthly injectable, which could offer less frequent dosing and improved gastrointestinal tolerability, potentially leading to better patient adherence and increased weight loss. MBX 4291 was created using the company's proprietary Precision Endocrine Peptide/PEP platform. A doctor holding a test tube of the biopharmaceutical company's NicAlert drug product while providing patient care. In preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss as tirzepatide, a weekly GLP-1/GIP co-agonist that is already approved. Furthermore, these preclinical studies showed an extended duration of action for MBX 4291's active component compared to tirzepatide, supporting the potential for once-monthly administration. MBX Biosciences Inc. (NASDAQ:MBX) is a clinical-stage biopharmaceutical company that discovers and develops precision peptide therapies for the treatment of endocrine and metabolic disorders. While we acknowledge the potential of MBX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Dangerous hidden side effect of Covid infection revealed by new study
Covid may prematurely age blood vessels by around five years, according to a new study, increasing the risk of heart attack and stroke. Research published in the European Heart Journal revealed that a Covid infection could accelerate the ageing of blood vessels, particularly in women. Vaccinated individuals show less stiffening in their arteries and stabilised symptoms over time in comparison to those who had not been protected against Covid. Lead researcher Professor Rosa Maria Bruno, from Université Paris Cité, said: "We know that Covid can directly affect blood vessels. We believe that this may result in what we call early vascular ageing, meaning that your blood vessels are older than your chronological age and you are more susceptible to heart disease. 'If that is happening, we need to identify who is at risk at an early stage to prevent heart attacks and strokes." The new study tested nearly 2,500 people from across the world, categorising them based on whether they had Covid and whether they had been hospitalised for it, both in a general ward and in an intensive care unit. Tests were taken six months after an infection and again after 12 months. It measured each person's vascular age with a device that examines how quickly a wave of blood pressure travels between the artery in the neck and the legs. The higher the measurement meant the stiffer the blood vessels, indicating a higher vascular age. It found that all three groups of patients who had a Covid infection had stiffer arteries compared to those who hadn't been affected. The average increase in women was 0.55 meters per second for those who had mild Covid, 0.60 for those who had been hospitalised, and 1.09 for those in intensive care. According to researchers, an increase of around 0.5 meters per second is "clinically relevant" and equivalent to ageing around five years. It also increases the risk of cardiovascular disease, like heart attack, stroke or sudden cardiac arrest, in 60-year-old women by 3 per cent. The difference between men and women could come down to immune systems, Prof Bruno added. She said: 'Women mount a more rapid and robust immune response, which can protect them from infection. However, this same response can also increase damage to blood vessels after the initial infection.' She said the virus acts on specific receptors in the body that are in the lining of the blood vessels. The virus will use these receptors to enter and infect cells. Last month, it was reported that a new strain of Covid had spread across the UK, accounting for the highest proportion of cases - around 30 per cent. Experts warned the Stratus strain was resisting immunity and had a unique symptom of giving people a hoarse voice.
